Tranexamic acid (TXA) is an antifibrinolytic agent that stabilizes clots by blocking the activation of plasminogen to plasmin, the enzyme that breaks down fibrin. Because of this action, TXA is used in a variety of clinical situations where reducing bleeding or improving clot stability is desired. Below is a snapshot of its most common medical uses.
| Clinical scenario | Typical indication | How it’s used |
|-------------------|-------------------|---------------|
| Heavy menstrual bleeding (menorrhagia) | To reduce menstrual blood loss and improve quality of life in women who do not respond to or cannot take hormonal therapy. | Oral tablets (usually 1 g twice daily for 5–7 days at the start of the period) or a single dose (e.g., 500 mg) during the bleeding episode. |
| Post‑partum hemorrhage (PPH) | First‑line adjunct to uterotonics (oxytocin, carboprost, misoprostol) in the prevention or treatment of uterine bleeding after delivery. | Intravenous infusion (e.g., 1 g over 10 minutes, repeated if needed) or a single 1 g IV dose; can also be given as 1 g IM if IV access is delayed. |
| Traumatic bleeding / hemorrhagic shock | Reduces blood loss and improves survival in patients with severe trauma, especially when combined with early plasma resuscitation. | IV infusion (1 g over 10 minutes, followed by a maintenance dose of 1 g every 6–12 hours) or a single 1 g IV dose in the first hour after injury. |
| Surgical bleeding (orthopedic, cardiac, ENT, dental, etc.) | Decreases intra‑operative blood loss and need for transfusion in many major surgeries. | IV infusion or pre‑operative IV/IM dose (1 g) often given 30 minutes before incision; dosing can be tailored to the procedure size. |
| Dysfunctional uterine bleeding (non‑menorrhagic) | To control bleeding in patients with uterine fibroids or other causes of heavy bleeding who are not candidates for hormonal therapy. | Oral 1 g twice daily for 5–7 days at onset of bleeding. |
| Hemophilia with inhibitors | Helps achieve hemostasis during bleeding episodes or surgical procedures when factor replacement is difficult. | IV infusion (dose depends on body weight; often 10 mg/kg) given before or during surgery/bleeding. |
| Upper‑GI or lower‑GI bleeding | Adjunct to endoscopic therapy in peptic ulcer bleeding, diverticular bleeding, and other causes of significant GI hemorrhage. | IV infusion (1 g over 10 minutes, then 1 g every 6–12 hours) or a single 1 g dose. |
| Dental and periodontal surgery | Reduces bleeding in patients on antiplatelet or anticoagulant therapy, or those with bleeding disorders. | IV 1 g or oral 1 g dose a few hours before the procedure. |
| Chronic kidney disease (CKD) – anemia management | Helps control bleeding from uremic platelet dysfunction in dialysis patients. | Oral 500 mg–1 g daily or IV 1 g during dialysis sessions; exact regimen depends on the center’s protocol. |
| Aneurysm surgery / endovascular procedures | Stabilizes clots to reduce intra‑operative bleeding. | IV infusion or bolus 1 g before or during the procedure. |
Key points to keep in mind
1. Mechanism – TXA blocks lysine‑binding sites on plasminogen, preventing plasmin formation and thereby slowing fibrin clot breakdown.
2. Safety – Generally well tolerated. The most common adverse effect is a transient, mild increase in serum creatinine. Rare but serious concerns include thromboembolic events (deep vein thrombosis, pulmonary embolism) and seizures (particularly at very high doses).
3. Contraindications – Active intravascular clotting, severe renal impairment (unless dose adjusted), and history of thromboembolic disease (unless benefit outweighs risk).
4. Drug interactions – No major interactions with other common medications, but careful monitoring is warranted in patients on anticoagulants or antiplatelet agents.
5. Formulations – Available as oral tablets, oral solutions, and IV infusions. Dosage is usually weight‑based for IV use and fixed for oral use in most outpatient settings.
6. Monitoring – Check renal function before initiating therapy; adjust dose in renal impairment (often 1 g every 12–24 hours). Watch for signs of excessive clotting or bleeding.
7. Special populations – In pediatric patients, dosing is usually 10 mg/kg IV (max 1 g) for bleeding episodes. In the elderly, renal function should be assessed because clearance of TXA is largely renal.
Bottom line
Tranexamic acid is a versatile, evidence‑based agent that reduces bleeding in many settings—from heavy periods and obstetric hemorrhage to trauma and major surgeries. Its use has been shown to decrease transfusion requirements, lower morbidity, and in some cases improve survival. As always, the decision to use TXA should be made in the context of the patient’s overall risk profile, the specific clinical scenario, and in consultation with the treating medical team.